ライフサイエンスコーパス: plasmablastic

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 re or unrecognized lymphoma subtypes such as plasmablastic and primary effusion lymphomas.

2 of high-grade/anaplastic, intermediate-grade/plasmablastic, and low-grade/plasmacytic cases with simi

3 Thus, ALK-positive plasmablastic B-cell lymphomas are more heterogeneous at

4 ene expression profile of PEL was defined as plasmablastic because it showed features of both immunob

5 In the multivariate analysis, plasmablastic classification was the most powerful progn

6 wed bone marrow aspirate slides to determine plasmablastic classification.

7 ls carry the stigmata of B lymphocytes, with plasmablastic features.

8 diseases, primary effusion lymphoma and the plasmablastic form of multicentric Castleman's disease.

9 Bcl-xl/Myc tumors are similar to a subset of plasmablastic human myelomas and provide insight into th

10 ranodal marginal zone lymphoma (n = 2, 11%), plasmablastic lymphoma (n = 1, 6%), and unspecified non-

11 Plasmablastic lymphoma (PBL) is an aggressive lymphoma c

12 MHC II and plasma cell markers in DLBCL and plasmablastic lymphoma (PBL).

13 Plasmablastic lymphoma associated with MCD is a new dise

14 Furthermore, we show that the frank plasmablastic lymphoma that develops in patients with th

15 ay fill this niche for the treatment of PEL, plasmablastic lymphoma, MM, and other ADK-expressing can

16 terogeneity of primary DLBCL and 1 that is a plasmablastic lymphoma.

17 Castleman disease (MCD), and MCD-associated plasmablastic lymphoma.

18 ollicles but may form microlymphoma or frank plasmablastic lymphoma.

19 sly, we reported that the K1 protein induced plasmablastic lymphomas in K1 transgenic mice, and that

20 phomas to monoclonal microlymphoma and frank plasmablastic lymphomas in MCD patients.

21 age, a small number of B-lineage tumors with plasmablastic morphology and expression of the full-leng

22 Tumors have a plasmablastic morphology and variable expression of CD13

23 ion was significantly worse in patients with plasmablastic morphology compared with those without (me

24 ficantly greater proportion of patients with plasmablastic morphology had abnormal cytogenetics compa

25 Plasmablastic morphology is a powerful independent predi

26 Plasmablastic morphology was considered to be present (p

27 eatures, such as lack of expression of CD20, plasmablastic morphology, and clinical course characteri

28 Each had plasmablastic morphology, showed immunoglobulin A restri

29 ndices, beta2-microglobulin, hemoglobin, and plasmablastic morphology.

30 e also identified three risk groups based on plasmablastic morphology: plasma-cell labeling index, la

31 HIV-associated plasmablastic multicentric Castleman disease is an incre

32 si's sarcoma, primary effusion lymphoma, and plasmablastic multicentric Castleman's disease.

33 tic morphology was considered to be present (plasmablastic myeloma) when 2% or more plasmablasts were

34 We studied the prognostic significance of plasmablastic (PB) multiple myeloma (MM) in Eastern Coop

35 ted with B-cell growth transformation, had a plasmablastic phenotype, and frequently expressed the pr

36 TIMP-1 expression in tumors with plasmacytic/plasmablastic phenotypes, including multiple myelomas.

37 Plasmablastic plasmacytomas from NFS.V(+) and SJL-beta2M

38 enes expressed by the most prevalent tumors, plasmablastic plasmacytomas, showed them to be most clos

39 d local therapy were not sufficient to treat plasmablastic posttransplant lymphoma even in localized

40 Plasmablastic posttransplant lymphoma is a rare subtype

41 Eight cases of plasmablastic posttransplant lymphoma were reported to t

42 gulation, indicating an arrested plasmacytic/plasmablastic stage of differentiation.

43 Plasmablastic tumors seemed to develop in an inflammator

44 nt factor in the pathogenesis of plasmacytic/plasmablastic tumors.

45 lymphoma that develops in patients with this plasmablastic variant of MCD is also positive for HHV-8

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。